Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Accumulated Expenses (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Accumulated Expenses for 16 consecutive years, with $96.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 18.57% to $96.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $96.9 million, a 18.57% decrease, with the full-year FY2025 number at $96.9 million, down 18.57% from a year prior.
  • Accumulated Expenses was $96.9 million for Q4 2025 at Myriad Genetics, down from $108.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $164.3 million in Q2 2023 to a low of $83.1 million in Q1 2021.
  • A 5-year average of $114.2 million and a median of $108.3 million in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 149.54% in 2021, then plummeted 47.73% in 2022.
  • Myriad Genetics' Accumulated Expenses stood at $161.7 million in 2021, then tumbled by 41.68% to $94.3 million in 2022, then increased by 20.78% to $113.9 million in 2023, then increased by 4.48% to $119.0 million in 2024, then decreased by 18.57% to $96.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Accumulated Expenses are $96.9 million (Q4 2025), $108.3 million (Q3 2025), and $100.6 million (Q2 2025).